
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Neurocrine Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration
Details : Collaboration leverages Sentia’s platform and Neurocrine’s expertise to develop novel CRF receptor antagonists.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
April 16, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Neurocrine Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Neurocrine Biosciences
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : Under the research collaboration, Sentia’s proprietary peptide-based platform will be used to discover novel compounds as corticotropin-releasing factor receptor antagonist for the treatment of hypothalamic-pituitary-adrenal axis modulated diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Neurocrine Biosciences
Deal Size : Undisclosed
Deal Type : Expanded Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Astressin B
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Neurocrine Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will utilize Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicines with the potential to treat a variety of hypothalamic-pituitary-adrenal (HPA)...
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
April 27, 2021
Lead Product(s) : Astressin B
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Neurocrine Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
